(231) used cytokine micro dialysis to detect real-time immune assays in GBM patients undergoing PD-1 and LAG-3 checkpoint inhibition, suggesting that the anti-LAG-3 and anti-PD-1 combination may have a similar immune response side effect profile to other checkpoint inhibitor combinations. This evidence concerns the gene PDCD1 and glioblastoma.